Home

Download

Statistics

Examples

Help

Contact

	Fusion Gene Summary
	Fusion Gene ORF analysis
	Fusion Genomic Features
	Fusion Protein Features
	Fusion Gene Sequence
	Fusion Gene PPI analysis
	Related Drugs
	Related Diseases

Fusion gene:MARK3-FRG1 (FusionGDB2 ID:51767)

Fusion Gene Summary for MARK3-FRG1

Fusion gene summary

Fusion gene information	Fusion gene name: MARK3-FRG1
	Fusion gene ID: 51767
		Hgene	Tgene
	Gene symbol	MARK3	FRG1
	Gene ID	4140	2483
	Gene name	microtubule affinity regulating kinase 3	FSHD region gene 1
	Synonyms	CTAK1\|KP78\|PAR1A\|Par-1a\|VIPB	FRG1A\|FSG1
	Cytomap	14q32.32-q32.33	4q35.2
	Type of gene	protein-coding	protein-coding
	Description	MAP/microtubule affinity-regulating kinase 3C-TAK1ELKL motif kinase 2EMK-2cdc25C-associated protein kinase 1protein kinase STK10ser/Thr protein kinase PAR-1serine/threonine-protein kinase p78	protein FRG1FSHD region gene 1 proteinfacioscapulohumeral muscular dystrophy region gene-1
	Modification date	20200313	20200313
	UniProtAcc	P27448	Q14331
	Ensembl transtripts involved in fusion gene	ENST00000561071, ENST00000216288, ENST00000303622, ENST00000335102, ENST00000416682, ENST00000429436, ENST00000440884, ENST00000553942,	ENST00000226798, ENST00000514482,
Fusion gene scores	* DoF score	23 X 15 X 10=3450	5 X 3 X 5=75
	# samples	25	5
	** MAII score	log2(25/3450*10)=-3.78659636189081 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0	log2(5/75*10)=-0.584962500721156 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0
Context	PubMed: MARK3 [Title/Abstract] AND FRG1 [Title/Abstract] AND fusion [Title/Abstract]
Most frequent breakpoint	MARK3(103894777)-FRG1(190878553), # samples:1
Anticipated loss of major functional domain due to fusion event.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner	Gene	GO ID	GO term	PubMed ID
Hgene	MARK3	GO:0018105	peptidyl-serine phosphorylation	9543386
Hgene	MARK3	GO:0032092	positive regulation of protein binding	9543386
Hgene	MARK3	GO:0035331	negative regulation of hippo signaling	28087714
Hgene	MARK3	GO:0036289	peptidyl-serine autophosphorylation	9543386

Fusion gene breakpoints across MARK3 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across FRG1 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0)
* All genome coordinats were lifted-over on hg19.
* Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser.

Source	Disease	Sample	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand
ChimerDB4	BRCA	TCGA-A8-A06U-01A	MARK3	chr14	103894777	+	FRG1	chr4	190878553	+

Top

Fusion Gene ORF analysis for MARK3-FRG1

Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure.
* Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser.

ORF	Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand
3UTR-3CDS	ENST00000561071	ENST00000226798	MARK3	chr14	103894777	+	FRG1	chr4	190878553	+
3UTR-3UTR	ENST00000561071	ENST00000514482	MARK3	chr14	103894777	+	FRG1	chr4	190878553	+
5CDS-3UTR	ENST00000216288	ENST00000514482	MARK3	chr14	103894777	+	FRG1	chr4	190878553	+
5CDS-3UTR	ENST00000303622	ENST00000514482	MARK3	chr14	103894777	+	FRG1	chr4	190878553	+
5CDS-3UTR	ENST00000335102	ENST00000514482	MARK3	chr14	103894777	+	FRG1	chr4	190878553	+
5CDS-3UTR	ENST00000416682	ENST00000514482	MARK3	chr14	103894777	+	FRG1	chr4	190878553	+
5CDS-3UTR	ENST00000429436	ENST00000514482	MARK3	chr14	103894777	+	FRG1	chr4	190878553	+
5CDS-3UTR	ENST00000440884	ENST00000514482	MARK3	chr14	103894777	+	FRG1	chr4	190878553	+
5CDS-3UTR	ENST00000553942	ENST00000514482	MARK3	chr14	103894777	+	FRG1	chr4	190878553	+
In-frame	ENST00000216288	ENST00000226798	MARK3	chr14	103894777	+	FRG1	chr4	190878553	+
In-frame	ENST00000303622	ENST00000226798	MARK3	chr14	103894777	+	FRG1	chr4	190878553	+
In-frame	ENST00000335102	ENST00000226798	MARK3	chr14	103894777	+	FRG1	chr4	190878553	+
In-frame	ENST00000416682	ENST00000226798	MARK3	chr14	103894777	+	FRG1	chr4	190878553	+
In-frame	ENST00000429436	ENST00000226798	MARK3	chr14	103894777	+	FRG1	chr4	190878553	+
In-frame	ENST00000440884	ENST00000226798	MARK3	chr14	103894777	+	FRG1	chr4	190878553	+
In-frame	ENST00000553942	ENST00000226798	MARK3	chr14	103894777	+	FRG1	chr4	190878553	+

ORFfinder result based on the fusion transcript sequence of in-frame fusion genes.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	Seq length (transcript)	BP loci (transcript)	Predicted start (transcript)	Predicted stop (transcript)	Seq length (amino acids)
ENST00000440884	MARK3	chr14	103894777	+	ENST00000226798	FRG1	chr4	190878553	+	1355	935	638	1279	213
ENST00000416682	MARK3	chr14	103894777	+	ENST00000226798	FRG1	chr4	190878553	+	1294	874	577	1218	213
ENST00000429436	MARK3	chr14	103894777	+	ENST00000226798	FRG1	chr4	190878553	+	1227	807	510	1151	213
ENST00000303622	MARK3	chr14	103894777	+	ENST00000226798	FRG1	chr4	190878553	+	1206	786	489	1130	213
ENST00000216288	MARK3	chr14	103894777	+	ENST00000226798	FRG1	chr4	190878553	+	887	467	170	811	213
ENST00000553942	MARK3	chr14	103894777	+	ENST00000226798	FRG1	chr4	190878553	+	762	342	45	686	213
ENST00000335102	MARK3	chr14	103894777	+	ENST00000226798	FRG1	chr4	190878553	+	717	297	0	641	213

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000440884	ENST00000226798	MARK3	chr14	103894777	+	FRG1	chr4	190878553	+	0.00771416	0.99228585
ENST00000416682	ENST00000226798	MARK3	chr14	103894777	+	FRG1	chr4	190878553	+	0.007659427	0.99234056
ENST00000429436	ENST00000226798	MARK3	chr14	103894777	+	FRG1	chr4	190878553	+	0.005194881	0.99480516
ENST00000303622	ENST00000226798	MARK3	chr14	103894777	+	FRG1	chr4	190878553	+	0.00615212	0.9938479
ENST00000216288	ENST00000226798	MARK3	chr14	103894777	+	FRG1	chr4	190878553	+	0.005921984	0.99407804
ENST00000553942	ENST00000226798	MARK3	chr14	103894777	+	FRG1	chr4	190878553	+	0.011285818	0.98871416
ENST00000335102	ENST00000226798	MARK3	chr14	103894777	+	FRG1	chr4	190878553	+	0.012265214	0.98773474

Top

Fusion Genomic Features for MARK3-FRG1

FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints.

Hgene

Hchr

Hbp

Hstrand

Tgene

Tchr

Tbp

Tstrand

1-p

p (fusion gene breakpoint)

Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page.

Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page.

Top

Fusion Protein Features for MARK3-FRG1

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr14:103894777/chr4:190878553)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Main function of each fusion partner protein. (from UniProt)

Hgene	Tgene
MARK3 P27448	FRG1 Q14331
FUNCTION: Serine/threonine-protein kinase (PubMed:23666762). Involved in the specific phosphorylation of microtubule-associated proteins for MAP2 and MAP4. Phosphorylates the microtubule-associated protein MAPT/TAU (PubMed:23666762). Phosphorylates CDC25C on 'Ser-216'. Regulates localization and activity of some histone deacetylases by mediating phosphorylation of HDAC7, promoting subsequent interaction between HDAC7 and 14-3-3 and export from the nucleus (PubMed:16980613). Negatively regulates the Hippo signaling pathway and antagonizes the phosphorylation of LATS1. Cooperates with DLG5 to inhibit the kinase activity of STK3/MST2 toward LATS1 (PubMed:28087714). {ECO:0000269\|PubMed:16980613, ECO:0000269\|PubMed:23666762, ECO:0000269\|PubMed:28087714}.	FUNCTION: Binds to mRNA in a sequence-independent manner. May play a role in regulation of pre-mRNA splicing or in the assembly of rRNA into ribosomal subunits. May be involved in mRNA transport. May be involved in epigenetic regulation of muscle differentiation through regulation of activity of the histone-lysine N-methyltransferase KMT5B. {ECO:0000269\|PubMed:11991638, ECO:0000269\|PubMed:15060122, ECO:0000269\|PubMed:20970242, ECO:0000269\|PubMed:21699900, ECO:0000269\|PubMed:23720823}.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at
download page

* Minus value of BPloci means that the break pointn is located before the CDS.

- In-frame and retained protein feature among the 13 regional features.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Hgene

MARK3

chr14:103894777

chr4:190878553

ENST00000216288

62_70

714.0

Nucleotide binding

ATP

Hgene

MARK3

chr14:103894777

chr4:190878553

ENST00000303622

62_70

730.0

Nucleotide binding

ATP

Hgene

MARK3

chr14:103894777

chr4:190878553

ENST00000416682

62_70

753.0

Nucleotide binding

ATP

Hgene

MARK3

chr14:103894777

chr4:190878553

ENST00000429436

62_70

754.0

Nucleotide binding

ATP

Hgene

MARK3

chr14:103894777

chr4:190878553

ENST00000440884

62_70

660.0

Nucleotide binding

ATP

Hgene

MARK3

chr14:103894777

chr4:190878553

ENST00000553942

62_70

745.0

Nucleotide binding

ATP

Tgene

FRG1

chr14:103894777

chr4:190878553

ENST00000226798

235_251

144

259.0

Motif

Bipartite nuclear localization signal

- In-frame and not-retained protein feature among the 13 regional features.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Hgene

MARK3

chr14:103894777

chr4:190878553

ENST00000216288

326_365

714.0

Domain

UBA

Hgene

MARK3

chr14:103894777

chr4:190878553

ENST00000216288

56_307

714.0

Domain

Protein kinase

Hgene

MARK3

chr14:103894777

chr4:190878553

ENST00000216288

704_753

714.0

Domain

KA1

Hgene

MARK3

chr14:103894777

chr4:190878553

ENST00000303622

326_365

730.0

Domain

UBA

Hgene

MARK3

chr14:103894777

chr4:190878553

ENST00000303622

56_307

730.0

Domain

Protein kinase

Hgene

MARK3

chr14:103894777

chr4:190878553

ENST00000303622

704_753

730.0

Domain

KA1

Hgene

MARK3

chr14:103894777

chr4:190878553

ENST00000416682

326_365

753.0

Domain

UBA

Hgene

MARK3

chr14:103894777

chr4:190878553

ENST00000416682

56_307

753.0

Domain

Protein kinase

Hgene

MARK3

chr14:103894777

chr4:190878553

ENST00000416682

704_753

753.0

Domain

KA1

Hgene

MARK3

chr14:103894777

chr4:190878553

ENST00000429436

326_365

754.0

Domain

UBA

Hgene

MARK3

chr14:103894777

chr4:190878553

ENST00000429436

56_307

754.0

Domain

Protein kinase

Hgene

MARK3

chr14:103894777

chr4:190878553

ENST00000429436

704_753

754.0

Domain

KA1

Hgene

MARK3

chr14:103894777

chr4:190878553

ENST00000440884

326_365

660.0

Domain

UBA

Hgene

MARK3

chr14:103894777

chr4:190878553

ENST00000440884

56_307

660.0

Domain

Protein kinase

Hgene

MARK3

chr14:103894777

chr4:190878553

ENST00000440884

704_753

660.0

Domain

KA1

Hgene

MARK3

chr14:103894777

chr4:190878553

ENST00000553942

326_365

745.0

Domain

UBA

Hgene

MARK3

chr14:103894777

chr4:190878553

ENST00000553942

56_307

745.0

Domain

Protein kinase

Hgene

MARK3

chr14:103894777

chr4:190878553

ENST00000553942

704_753

745.0

Domain

KA1

Tgene

FRG1

chr14:103894777

chr4:190878553

ENST00000226798

8_32

144

259.0

Compositional bias

Note=Lys-rich

Tgene

FRG1

chr14:103894777

chr4:190878553

ENST00000226798

22_32

144

259.0

Motif

Nuclear localization signal

Top

Fusion Gene Sequence for MARK3-FRG1

For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones.

>51767_51767_1_MARK3-FRG1_MARK3_chr14_103894777_ENST00000216288_FRG1_chr4_190878553_ENST00000226798_length(transcript)=887nt_BP=467nt
GACGGCCCGGGCCAGGCCCGGGATCTAGACGGCCGTAGGGGGAAGGGAGCCGCCCTCCCCACGGCGCCTTTTCGGAACTGCCGTGGACTC
GAGGACGCTGGTCGCCGGCCTCCTAGGGCTGTGCTGTTTTGTTTTGACCCTCGCATTGTGCAGAATTAAAGTGCAGTAAAATGTCCACTA
GGACCCCATTGCCAACGGTGAATGAACGAGACACTGAAAACCACACGTCACATGGAGATGGGCGTCAAGAAGTTACCTCTCGTACCAGCC
GCTCAGGAGCTCGGTGTAGAAACTCTATAGCCTCCTGTGCAGATGAACAACCTCACATCGGAAACTACAGACTGTTGAAAACAATCGGCA
AGGGGAATTTTGCAAAAGTAAAATTGGCAAGACATATCCTTACAGGCAGAGAGGTTGCAATAAAAATAATTGACAAAACTCAGTTGAATC
CAACAAGTCTACAAAAGGGGAAAATGGCTTTGTTGGCCTCAAATAGCTGCTTTATTAGATGCAATGAAGCAGGGGACATAGAAGCAAAAA
GTAAAACAGCAGGAGAAGAAGAAATGATCAAGATTAGATCCTGTGCTGAAAGAGAAACCAAGAAAAAAGATGACATTCCAGAAGAAGACA
AAGGAAATGTAAAACAATGTGAAATCAATTATGTAAAGAAATTTCAGAGCTTCCAAGACCACAAACTTAAAATAAGTAAAGAAGACAGTA
AAATTCTTAAAAAGGCTCGGAAAGATGGATTTTTGCATGAGACGCTTCTGGACAGGAGAGCCAAATTGAAAGCCGACAGATACTGCAAGT

>51767_51767_1_MARK3-FRG1_MARK3_chr14_103894777_ENST00000216288_FRG1_chr4_190878553_ENST00000226798_length(amino acids)=213AA_BP=99
MSTRTPLPTVNERDTENHTSHGDGRQEVTSRTSRSGARCRNSIASCADEQPHIGNYRLLKTIGKGNFAKVKLARHILTGREVAIKIIDKT
QLNPTSLQKGKMALLASNSCFIRCNEAGDIEAKSKTAGEEEMIKIRSCAERETKKKDDIPEEDKGNVKQCEINYVKKFQSFQDHKLKISK

--------------------------------------------------------------
>51767_51767_2_MARK3-FRG1_MARK3_chr14_103894777_ENST00000303622_FRG1_chr4_190878553_ENST00000226798_length(transcript)=1206nt_BP=786nt
GCTCCATGGTCGGCGCCCACAGCCCGCGGCGGCCTGTCTTGCGCTCCACTTCCTTCACATCCTCCTCCGCCTCCTCGTTTTCAGGCGCCG
CCGGCGGCGCTGTGTGGAGGCCCGCGAGCTGAAATTCGCGGTGCGACGGGAGGGAGTGGAGAAGGAGGTGAGGGGGCCCAGGATCGCGGG
GCGCCCTGAGGCAAGGGGACGCCGGCGGGCCGAAGCGCAGCCCGCCGCCCGCAGGCTCGGCTCCGCCACTGCCGCCCTCCCGGTCTCCTC
GCCTCGGCCGCCGAGGCAGGGAGAGAATGAGCCCCGGGACCCGCCGGGGGACGGCCCGGGCCAGGCCCGGGATCTAGACGGCCGTAGGGG
GAAGGGAGCCGCCCTCCCCACGGCGCCTTTTCGGAACTGCCGTGGACTCGAGGACGCTGGTCGCCGGCCTCCTAGGGCTGTGCTGTTTTG
TTTTGACCCTCGCATTGTGCAGAATTAAAGTGCAGTAAAATGTCCACTAGGACCCCATTGCCAACGGTGAATGAACGAGACACTGAAAAC
CACACGTCACATGGAGATGGGCGTCAAGAAGTTACCTCTCGTACCAGCCGCTCAGGAGCTCGGTGTAGAAACTCTATAGCCTCCTGTGCA
GATGAACAACCTCACATCGGAAACTACAGACTGTTGAAAACAATCGGCAAGGGGAATTTTGCAAAAGTAAAATTGGCAAGACATATCCTT
ACAGGCAGAGAGGTTGCAATAAAAATAATTGACAAAACTCAGTTGAATCCAACAAGTCTACAAAAGGGGAAAATGGCTTTGTTGGCCTCA
AATAGCTGCTTTATTAGATGCAATGAAGCAGGGGACATAGAAGCAAAAAGTAAAACAGCAGGAGAAGAAGAAATGATCAAGATTAGATCC
TGTGCTGAAAGAGAAACCAAGAAAAAAGATGACATTCCAGAAGAAGACAAAGGAAATGTAAAACAATGTGAAATCAATTATGTAAAGAAA
TTTCAGAGCTTCCAAGACCACAAACTTAAAATAAGTAAAGAAGACAGTAAAATTCTTAAAAAGGCTCGGAAAGATGGATTTTTGCATGAG
ACGCTTCTGGACAGGAGAGCCAAATTGAAAGCCGACAGATACTGCAAGTGACTGGGATTTTTGTTTCTGCCTTATCTTTCTGTGTTTTTT

>51767_51767_2_MARK3-FRG1_MARK3_chr14_103894777_ENST00000303622_FRG1_chr4_190878553_ENST00000226798_length(amino acids)=213AA_BP=99
MSTRTPLPTVNERDTENHTSHGDGRQEVTSRTSRSGARCRNSIASCADEQPHIGNYRLLKTIGKGNFAKVKLARHILTGREVAIKIIDKT
QLNPTSLQKGKMALLASNSCFIRCNEAGDIEAKSKTAGEEEMIKIRSCAERETKKKDDIPEEDKGNVKQCEINYVKKFQSFQDHKLKISK

--------------------------------------------------------------
>51767_51767_3_MARK3-FRG1_MARK3_chr14_103894777_ENST00000335102_FRG1_chr4_190878553_ENST00000226798_length(transcript)=717nt_BP=297nt
ATGTCCACTAGGACCCCATTGCCAACGGTGAATGAACGAGACACTGAAAACCACACGTCACATGGAGATGGGCGTCAAGAAGTTACCTCT
CGTACCAGCCGCTCAGGAGCTCGGTGTAGAAACTCTATAGCCTCCTGTGCAGATGAACAACCTCACATCGGAAACTACAGACTGTTGAAA
ACAATCGGCAAGGGGAATTTTGCAAAAGTAAAATTGGCAAGACATATCCTTACAGGCAGAGAGGTTGCAATAAAAATAATTGACAAAACT
CAGTTGAATCCAACAAGTCTACAAAAGGGGAAAATGGCTTTGTTGGCCTCAAATAGCTGCTTTATTAGATGCAATGAAGCAGGGGACATA
GAAGCAAAAAGTAAAACAGCAGGAGAAGAAGAAATGATCAAGATTAGATCCTGTGCTGAAAGAGAAACCAAGAAAAAAGATGACATTCCA
GAAGAAGACAAAGGAAATGTAAAACAATGTGAAATCAATTATGTAAAGAAATTTCAGAGCTTCCAAGACCACAAACTTAAAATAAGTAAA
GAAGACAGTAAAATTCTTAAAAAGGCTCGGAAAGATGGATTTTTGCATGAGACGCTTCTGGACAGGAGAGCCAAATTGAAAGCCGACAGA

>51767_51767_3_MARK3-FRG1_MARK3_chr14_103894777_ENST00000335102_FRG1_chr4_190878553_ENST00000226798_length(amino acids)=213AA_BP=99
MSTRTPLPTVNERDTENHTSHGDGRQEVTSRTSRSGARCRNSIASCADEQPHIGNYRLLKTIGKGNFAKVKLARHILTGREVAIKIIDKT
QLNPTSLQKGKMALLASNSCFIRCNEAGDIEAKSKTAGEEEMIKIRSCAERETKKKDDIPEEDKGNVKQCEINYVKKFQSFQDHKLKISK

--------------------------------------------------------------
>51767_51767_4_MARK3-FRG1_MARK3_chr14_103894777_ENST00000416682_FRG1_chr4_190878553_ENST00000226798_length(transcript)=1294nt_BP=874nt
GCAGCGGCGGCCAGCAGGGCGGAGGCTGAGGCAGCAAGCTCGCTAGAGAGGGAGAAGCAGTCGGGCGCAGGCGCCTCCTCCGCAGCCCGC
TCCATGGTCGGCGCCCACAGCCCGCGGCGGCCTGTCTTGCGCTCCACTTCCTTCACATCCTCCTCCGCCTCCTCGTTTTCAGGCGCCGCC
GGCGGCGCTGTGTGGAGGCCCGCGAGCTGAAATTCGCGGTGCGACGGGAGGGAGTGGAGAAGGAGGTGAGGGGGCCCAGGATCGCGGGGC
GCCCTGAGGCAAGGGGACGCCGGCGGGCCGAAGCGCAGCCCGCCGCCCGCAGGCTCGGCTCCGCCACTGCCGCCCTCCCGGTCTCCTCGC
CTCGGCCGCCGAGGCAGGGAGAGAATGAGCCCCGGGACCCGCCGGGGGACGGCCCGGGCCAGGCCCGGGATCTAGACGGCCGTAGGGGGA
AGGGAGCCGCCCTCCCCACGGCGCCTTTTCGGAACTGCCGTGGACTCGAGGACGCTGGTCGCCGGCCTCCTAGGGCTGTGCTGTTTTGTT
TTGACCCTCGCATTGTGCAGAATTAAAGTGCAGTAAAATGTCCACTAGGACCCCATTGCCAACGGTGAATGAACGAGACACTGAAAACCA
CACGTCACATGGAGATGGGCGTCAAGAAGTTACCTCTCGTACCAGCCGCTCAGGAGCTCGGTGTAGAAACTCTATAGCCTCCTGTGCAGA
TGAACAACCTCACATCGGAAACTACAGACTGTTGAAAACAATCGGCAAGGGGAATTTTGCAAAAGTAAAATTGGCAAGACATATCCTTAC
AGGCAGAGAGGTTGCAATAAAAATAATTGACAAAACTCAGTTGAATCCAACAAGTCTACAAAAGGGGAAAATGGCTTTGTTGGCCTCAAA
TAGCTGCTTTATTAGATGCAATGAAGCAGGGGACATAGAAGCAAAAAGTAAAACAGCAGGAGAAGAAGAAATGATCAAGATTAGATCCTG
TGCTGAAAGAGAAACCAAGAAAAAAGATGACATTCCAGAAGAAGACAAAGGAAATGTAAAACAATGTGAAATCAATTATGTAAAGAAATT
TCAGAGCTTCCAAGACCACAAACTTAAAATAAGTAAAGAAGACAGTAAAATTCTTAAAAAGGCTCGGAAAGATGGATTTTTGCATGAGAC
GCTTCTGGACAGGAGAGCCAAATTGAAAGCCGACAGATACTGCAAGTGACTGGGATTTTTGTTTCTGCCTTATCTTTCTGTGTTTTTTTC

>51767_51767_4_MARK3-FRG1_MARK3_chr14_103894777_ENST00000416682_FRG1_chr4_190878553_ENST00000226798_length(amino acids)=213AA_BP=99
MSTRTPLPTVNERDTENHTSHGDGRQEVTSRTSRSGARCRNSIASCADEQPHIGNYRLLKTIGKGNFAKVKLARHILTGREVAIKIIDKT
QLNPTSLQKGKMALLASNSCFIRCNEAGDIEAKSKTAGEEEMIKIRSCAERETKKKDDIPEEDKGNVKQCEINYVKKFQSFQDHKLKISK

--------------------------------------------------------------
>51767_51767_5_MARK3-FRG1_MARK3_chr14_103894777_ENST00000429436_FRG1_chr4_190878553_ENST00000226798_length(transcript)=1227nt_BP=807nt
CAGGCGCCTCCTCCGCAGCCCGCTCCATGGTCGGCGCCCACAGCCCGCGGCGGCCTGTCTTGCGCTCCACTTCCTTCACATCCTCCTCCG
CCTCCTCGTTTTCAGGCGCCGCCGGCGGCGCTGTGTGGAGGCCCGCGAGCTGAAATTCGCGGTGCGACGGGAGGGAGTGGAGAAGGAGGT
GAGGGGGCCCAGGATCGCGGGGCGCCCTGAGGCAAGGGGACGCCGGCGGGCCGAAGCGCAGCCCGCCGCCCGCAGGCTCGGCTCCGCCAC
TGCCGCCCTCCCGGTCTCCTCGCCTCGGCCGCCGAGGCAGGGAGAGAATGAGCCCCGGGACCCGCCGGGGGACGGCCCGGGCCAGGCCCG
GGATCTAGACGGCCGTAGGGGGAAGGGAGCCGCCCTCCCCACGGCGCCTTTTCGGAACTGCCGTGGACTCGAGGACGCTGGTCGCCGGCC
TCCTAGGGCTGTGCTGTTTTGTTTTGACCCTCGCATTGTGCAGAATTAAAGTGCAGTAAAATGTCCACTAGGACCCCATTGCCAACGGTG
AATGAACGAGACACTGAAAACCACACGTCACATGGAGATGGGCGTCAAGAAGTTACCTCTCGTACCAGCCGCTCAGGAGCTCGGTGTAGA
AACTCTATAGCCTCCTGTGCAGATGAACAACCTCACATCGGAAACTACAGACTGTTGAAAACAATCGGCAAGGGGAATTTTGCAAAAGTA
AAATTGGCAAGACATATCCTTACAGGCAGAGAGGTTGCAATAAAAATAATTGACAAAACTCAGTTGAATCCAACAAGTCTACAAAAGGGG
AAAATGGCTTTGTTGGCCTCAAATAGCTGCTTTATTAGATGCAATGAAGCAGGGGACATAGAAGCAAAAAGTAAAACAGCAGGAGAAGAA
GAAATGATCAAGATTAGATCCTGTGCTGAAAGAGAAACCAAGAAAAAAGATGACATTCCAGAAGAAGACAAAGGAAATGTAAAACAATGT
GAAATCAATTATGTAAAGAAATTTCAGAGCTTCCAAGACCACAAACTTAAAATAAGTAAAGAAGACAGTAAAATTCTTAAAAAGGCTCGG
AAAGATGGATTTTTGCATGAGACGCTTCTGGACAGGAGAGCCAAATTGAAAGCCGACAGATACTGCAAGTGACTGGGATTTTTGTTTCTG

>51767_51767_5_MARK3-FRG1_MARK3_chr14_103894777_ENST00000429436_FRG1_chr4_190878553_ENST00000226798_length(amino acids)=213AA_BP=99
MSTRTPLPTVNERDTENHTSHGDGRQEVTSRTSRSGARCRNSIASCADEQPHIGNYRLLKTIGKGNFAKVKLARHILTGREVAIKIIDKT
QLNPTSLQKGKMALLASNSCFIRCNEAGDIEAKSKTAGEEEMIKIRSCAERETKKKDDIPEEDKGNVKQCEINYVKKFQSFQDHKLKISK

--------------------------------------------------------------
>51767_51767_6_MARK3-FRG1_MARK3_chr14_103894777_ENST00000440884_FRG1_chr4_190878553_ENST00000226798_length(transcript)=1355nt_BP=935nt
GGAAGCCGAGGGGCGGCCATCTTGGCTCCGTGAGGCTCTGAGGTGCCGGGGTGCGGCGGCGGCAGCGGCGGCCAGCAGGGCGGAGGCTGA
GGCAGCAAGCTCGCTAGAGAGGGAGAAGCAGTCGGGCGCAGGCGCCTCCTCCGCAGCCCGCTCCATGGTCGGCGCCCACAGCCCGCGGCG
GCCTGTCTTGCGCTCCACTTCCTTCACATCCTCCTCCGCCTCCTCGTTTTCAGGCGCCGCCGGCGGCGCTGTGTGGAGGCCCGCGAGCTG
AAATTCGCGGTGCGACGGGAGGGAGTGGAGAAGGAGGTGAGGGGGCCCAGGATCGCGGGGCGCCCTGAGGCAAGGGGACGCCGGCGGGCC
GAAGCGCAGCCCGCCGCCCGCAGGCTCGGCTCCGCCACTGCCGCCCTCCCGGTCTCCTCGCCTCGGCCGCCGAGGCAGGGAGAGAATGAG
CCCCGGGACCCGCCGGGGGACGGCCCGGGCCAGGCCCGGGATCTAGACGGCCGTAGGGGGAAGGGAGCCGCCCTCCCCACGGCGCCTTTT
CGGAACTGCCGTGGACTCGAGGACGCTGGTCGCCGGCCTCCTAGGGCTGTGCTGTTTTGTTTTGACCCTCGCATTGTGCAGAATTAAAGT
GCAGTAAAATGTCCACTAGGACCCCATTGCCAACGGTGAATGAACGAGACACTGAAAACCACACGTCACATGGAGATGGGCGTCAAGAAG
TTACCTCTCGTACCAGCCGCTCAGGAGCTCGGTGTAGAAACTCTATAGCCTCCTGTGCAGATGAACAACCTCACATCGGAAACTACAGAC
TGTTGAAAACAATCGGCAAGGGGAATTTTGCAAAAGTAAAATTGGCAAGACATATCCTTACAGGCAGAGAGGTTGCAATAAAAATAATTG
ACAAAACTCAGTTGAATCCAACAAGTCTACAAAAGGGGAAAATGGCTTTGTTGGCCTCAAATAGCTGCTTTATTAGATGCAATGAAGCAG
GGGACATAGAAGCAAAAAGTAAAACAGCAGGAGAAGAAGAAATGATCAAGATTAGATCCTGTGCTGAAAGAGAAACCAAGAAAAAAGATG
ACATTCCAGAAGAAGACAAAGGAAATGTAAAACAATGTGAAATCAATTATGTAAAGAAATTTCAGAGCTTCCAAGACCACAAACTTAAAA
TAAGTAAAGAAGACAGTAAAATTCTTAAAAAGGCTCGGAAAGATGGATTTTTGCATGAGACGCTTCTGGACAGGAGAGCCAAATTGAAAG
CCGACAGATACTGCAAGTGACTGGGATTTTTGTTTCTGCCTTATCTTTCTGTGTTTTTTTCTGAATAAAATATTCAGAGGAAATGCTTTT

>51767_51767_6_MARK3-FRG1_MARK3_chr14_103894777_ENST00000440884_FRG1_chr4_190878553_ENST00000226798_length(amino acids)=213AA_BP=99
MSTRTPLPTVNERDTENHTSHGDGRQEVTSRTSRSGARCRNSIASCADEQPHIGNYRLLKTIGKGNFAKVKLARHILTGREVAIKIIDKT
QLNPTSLQKGKMALLASNSCFIRCNEAGDIEAKSKTAGEEEMIKIRSCAERETKKKDDIPEEDKGNVKQCEINYVKKFQSFQDHKLKISK

--------------------------------------------------------------
>51767_51767_7_MARK3-FRG1_MARK3_chr14_103894777_ENST00000553942_FRG1_chr4_190878553_ENST00000226798_length(transcript)=762nt_BP=342nt
GTTTTGTTTTGACCCTCGCATTGTGCAGAATTAAAGTGCAGTAAAATGTCCACTAGGACCCCATTGCCAACGGTGAATGAACGAGACACT
GAAAACCACACGTCACATGGAGATGGGCGTCAAGAAGTTACCTCTCGTACCAGCCGCTCAGGAGCTCGGTGTAGAAACTCTATAGCCTCC
TGTGCAGATGAACAACCTCACATCGGAAACTACAGACTGTTGAAAACAATCGGCAAGGGGAATTTTGCAAAAGTAAAATTGGCAAGACAT
ATCCTTACAGGCAGAGAGGTTGCAATAAAAATAATTGACAAAACTCAGTTGAATCCAACAAGTCTACAAAAGGGGAAAATGGCTTTGTTG
GCCTCAAATAGCTGCTTTATTAGATGCAATGAAGCAGGGGACATAGAAGCAAAAAGTAAAACAGCAGGAGAAGAAGAAATGATCAAGATT
AGATCCTGTGCTGAAAGAGAAACCAAGAAAAAAGATGACATTCCAGAAGAAGACAAAGGAAATGTAAAACAATGTGAAATCAATTATGTA
AAGAAATTTCAGAGCTTCCAAGACCACAAACTTAAAATAAGTAAAGAAGACAGTAAAATTCTTAAAAAGGCTCGGAAAGATGGATTTTTG
CATGAGACGCTTCTGGACAGGAGAGCCAAATTGAAAGCCGACAGATACTGCAAGTGACTGGGATTTTTGTTTCTGCCTTATCTTTCTGTG

>51767_51767_7_MARK3-FRG1_MARK3_chr14_103894777_ENST00000553942_FRG1_chr4_190878553_ENST00000226798_length(amino acids)=213AA_BP=99
MSTRTPLPTVNERDTENHTSHGDGRQEVTSRTSRSGARCRNSIASCADEQPHIGNYRLLKTIGKGNFAKVKLARHILTGREVAIKIIDKT
QLNPTSLQKGKMALLASNSCFIRCNEAGDIEAKSKTAGEEEMIKIRSCAERETKKKDDIPEEDKGNVKQCEINYVKKFQSFQDHKLKISK

--------------------------------------------------------------

Top

Fusion Gene PPI Analysis for MARK3-FRG1

Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in
ChiPPI page.

Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160)

Hgene

Hgene's interactors

Tgene

Tgene's interactors

- Retained PPIs in in-frame fusion.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Still interaction with

- Lost PPIs in in-frame fusion.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Interaction lost with

- Retained PPIs, but lost function due to frame-shift fusion.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Interaction lost with

Top

Related Drugs for MARK3-FRG1

Drugs targeting genes involved in this fusion gene.
(DrugBank Version 5.1.8 2021-05-08)

Partner

Gene

UniProtAcc

DrugBank ID

Drug name

Drug activity

Drug type

Drug status

Top

Related Diseases for MARK3-FRG1

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner

Gene

Disease ID

Disease name

# pubmeds

Source